niacin + rosuvastatin

Niacin + rosuvastatin is a combination therapy of two lipid-modifying agents used in the management of dyslipidemia. Niacin (vitamin B3) primarily raises high-density lipoprotein (HDL) cholesterol and lowers triglycerides, while rosuvastatin is a statin that inhibits HMG-CoA reductase, resulting in reduced low-density lipoprotein (LDL) cholesterol and total cholesterol. This combination targets atherogenic dyslipidemia by addressing multiple lipid parameters and is sometimes considered for patients with combined hyperlipidemia who have low HDL and elevated triglycerides. However, combining niacin with rosuvastatin can increase the risk of adverse effects, particularly myopathy and rhabdomyolysis, and is generally reserved for selected patients under close medical supervision[1][2][3][4][5].